Citrate Formulation Determines Filter Lifespan during Continuous Veno-Venous Hemofiltration: A Prospective Cohort Study
Authors:
- Patrick M. HonoréPHPatrick M. Honoré
- Sean M. BagshawSBSean M. Bagshaw
- Marc DiltoerMDMarc Diltoer
- Herbert D. SpapenHSHerbert D. Spapen
- 22 August 2015
- journal article
- research article
- Published by S. Karger AG in Blood Purification
- Vol. 40 (3) , 194-202
Abstract
Introduction: We conducted an 8-month prospective single-center observational study in patients with acute kidney injury treated with continuous veno-venous hemofiltration (CVVH) to compare the impact of two citrate formulations on filter lifespan (FLS). Methods: Patients received CVVH at a delivered dose of 25 ml/kg/h. Multivariable linear regression was performed to assess the influence of different variables on circuit lifespan. Results: We included 59 patients, 28 received the 10/2 formulation and 31 received the 18/0 formulation. Median (interquartile range) FLS was significantly prolonged with the 18/0 solution compared with the 10/2 solution (4.10 (2.45-5.75) vs. 2.68 (0.47-4.99) days, p = 0.001). No confounding variables (difference in ionized calcium target, citrate flow or dose, platelet count, hematocrit, vascular access location) affecting filter capacity or lifespan between the 2 formulations were identified. Conclusions: Under similar conditions of CVVH and calcium targets, a Prismocitrate 18/0 formulation significantly improved FLS as compared with Prismocitrate 10/2.Keywords
This publication has 17 references indexed in Scilit:
- A Retrospective Review of the Use of Regional Citrate Anticoagulation in Continuous Venovenous Hemofiltration for Critically Ill PatientsCritical Care Research and Practice, 2013
- Predilution versus Postdilution Continuous Venovenous Hemofiltration: No Effect on Filter Life and Azotemic Control in Critically Ill Patients on HeparinASAIO Journal, 2011
- THE CLINICAL APPLICATION OF CRRT—CURRENT STATUS: Anticoagulation for Continuous Renal Replacement TherapySeminars in Dialysis, 2009
- Citrate anticoagulation for continuous venovenous hemofiltration*Critical Care Medicine, 2009
- Acquired Deficit of Antithrombin and Role of Supplementation in Septic Patients During Continuous Veno-Venous HemofiltrationASAIO Journal, 2008
- Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?Intensive Care Medicine, 2006
- Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysisNephrology Dialysis Transplantation, 2005
- Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patientsCritical Care Medicine, 2003
- Pre-Dilution vs. Post-Dilution during Continuous Veno-Venous Hemofiltration: Impact on Filter Life and Azotemic ControlNephron Clinical Practice, 2003
- POSSIBLE STRATEGIES TO PROLONG CIRCUIT LIFE DURING HEMOFILTRATION: THREE CONTROLLED STUDIESRenal Failure, 2002